Amplyx is committed to developing safe and effective first-in-class products for the treatment of life-threatening diseases in immunocompromised patients. Our goal is to provide access to our investigational therapies at the appropriate time and in the correct manner for patients.
Amplyx believes that the most appropriate mechanism to access investigational therapies is in the context of a clinical trial. We recognize, however, that there are circumstances that may arise that prohibit a patient’s participation in a clinical trial. At this time, Amplyx’s Expanded Access program is currently under development. We will update this page with additional information on this program once it is available. If you have any questions, please contact email@example.com.